Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
T cell proliferation-related regulator genes
immunity
lung adenocarcinoma
mutation
predictive risk model
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
01
2023
accepted:
24
03
2023
medline:
21
4
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
Lung adenocarcinoma (LUAD), the major lung cancer histotype, represents 40% lung cancers. Currently, outcomes are remarkably different in LUAD patients with similar AJCC/UICC-TNM features. T cell proliferation-related regulator genes (TPRGs) relate to the proliferation, activity and function of T cells and tumor progression. The values of TPRGs in classifying LUAD patients and predicting outcomes remain unknown. Gene expression profile and corresponding clinical data were downloaded from TCGA and the GEO databases. We systematically analyzed the expression profile characteristics of 35 TPRGs in LUAD patients and investigated the differences in overall survival (OS), biology pathway, immunity and somatic mutation between different TPRGs-related subtypes. Subsequently, we constructed a TPRGs-related risk model in TCGA cohort to quantify risk scores using LASSO cox regression analysis and then validated this risk model in two GEO cohorts. LUAD patients were divided into high- and low-risk subtypes according to the median risk score. We systematically compared the biology pathway, immunity, somatic mutation and drug susceptibility between the two risk subtypes. Finally, we validate biological functions of two TPRGs-encoded proteins (DCLRE1B and HOMER1) in LUAD cells A549. We identified different TPRGs-related subtypes (including cluster 1/cluster A and its counterpart cluster 2/cluster B). Compared to the cluster 1/cluster A subtype, cluster 2/cluster B subtype tended to have a prominent survival advantage with an immunosuppressive microenvironment and a higher somatic mutation frequency. Then, we constructed a TPRGs-related 6-gene risk model. The high-risk subtype characterized by higher somatic mutation frequency and lower immunotherapy response had a worse prognosis. This risk model was an independent prognostic factor and showed to be reliable and accurate for LUAD classification. Furthermore, subtypes with different risk scores were significantly associated with drug sensitivity. DCLRE1B and HOMER1 suppressed cell proliferation, migration and invasion in LUAD cells A549, which was in line with their prognostic values. We construed a novel stratification model of LUAD based on TPRGs, which can accurately and reliably predict the prognosis and might be used as a predictive tool for LUAD patients.
Sections du résumé
Background
Lung adenocarcinoma (LUAD), the major lung cancer histotype, represents 40% lung cancers. Currently, outcomes are remarkably different in LUAD patients with similar AJCC/UICC-TNM features. T cell proliferation-related regulator genes (TPRGs) relate to the proliferation, activity and function of T cells and tumor progression. The values of TPRGs in classifying LUAD patients and predicting outcomes remain unknown.
Methods
Gene expression profile and corresponding clinical data were downloaded from TCGA and the GEO databases. We systematically analyzed the expression profile characteristics of 35 TPRGs in LUAD patients and investigated the differences in overall survival (OS), biology pathway, immunity and somatic mutation between different TPRGs-related subtypes. Subsequently, we constructed a TPRGs-related risk model in TCGA cohort to quantify risk scores using LASSO cox regression analysis and then validated this risk model in two GEO cohorts. LUAD patients were divided into high- and low-risk subtypes according to the median risk score. We systematically compared the biology pathway, immunity, somatic mutation and drug susceptibility between the two risk subtypes. Finally, we validate biological functions of two TPRGs-encoded proteins (DCLRE1B and HOMER1) in LUAD cells A549.
Results
We identified different TPRGs-related subtypes (including cluster 1/cluster A and its counterpart cluster 2/cluster B). Compared to the cluster 1/cluster A subtype, cluster 2/cluster B subtype tended to have a prominent survival advantage with an immunosuppressive microenvironment and a higher somatic mutation frequency. Then, we constructed a TPRGs-related 6-gene risk model. The high-risk subtype characterized by higher somatic mutation frequency and lower immunotherapy response had a worse prognosis. This risk model was an independent prognostic factor and showed to be reliable and accurate for LUAD classification. Furthermore, subtypes with different risk scores were significantly associated with drug sensitivity. DCLRE1B and HOMER1 suppressed cell proliferation, migration and invasion in LUAD cells A549, which was in line with their prognostic values.
Conclusion
We construed a novel stratification model of LUAD based on TPRGs, which can accurately and reliably predict the prognosis and might be used as a predictive tool for LUAD patients.
Identifiants
pubmed: 37077919
doi: 10.3389/fimmu.2023.1148483
pmc: PMC10106713
doi:
Substances chimiques
DCLRE1B protein, human
EC 3.1.-
Exodeoxyribonucleases
EC 3.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1148483Informations de copyright
Copyright © 2023 Yang, Zhu and Gong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2022 Jan 07;12:799455
pubmed: 35069581
Front Immunol. 2019 Feb 01;9:3101
pubmed: 30774636
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Rev Cancer. 2019 Jan;19(1):9-31
pubmed: 30532012
Front Immunol. 2022 Sep 23;13:970949
pubmed: 36211359
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Oncotarget. 2016 Dec 20;7(51):84675-84687
pubmed: 27835869
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Surg Pathol Clin. 2020 Mar;13(1):17-33
pubmed: 32005431
Tumour Biol. 2016 Sep;37(9):12713-12723
pubmed: 27448302
Cancer Prev Res (Phila). 2018 Mar;11(3):143-156
pubmed: 29246957
Eur J Immunol. 2019 Aug;49(8):1140-1146
pubmed: 31257581
Surg Today. 2018 Jan;48(1):1-8
pubmed: 28280984
Biochem J. 2010 Oct 15;431(2):245-55
pubmed: 20704563
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
J Oncol. 2022 Aug 31;2022:8115474
pubmed: 36090896
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Cells. 2020 Oct 16;9(10):
pubmed: 33081387
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Oncogene. 2021 Apr;40(16):2817-2829
pubmed: 33707749
Cancer Cell. 2021 Feb 8;39(2):154-173
pubmed: 33125859
Cancer Lett. 2017 May 28;394:76-87
pubmed: 28254412
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Nature. 2022 Mar;603(7902):728-735
pubmed: 35296855
J Thorac Oncol. 2020 Sep;15(9):1409-1424
pubmed: 32522712
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 34260682
Semin Cancer Biol. 2020 Oct;65:51-64
pubmed: 31874279
Cancers (Basel). 2019 Oct 21;11(10):
pubmed: 31640258
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Hum Vaccin Immunother. 2017 Nov 2;13(11):2575-2582
pubmed: 28362548
Pharmaceuticals (Basel). 2021 Aug 24;14(9):
pubmed: 34577535
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Cancer Immunol Res. 2016 Sep 2;4(9):734-43
pubmed: 27354337
J Thorac Oncol. 2016 Jun;11(6):789-800
pubmed: 26845192
Front Genet. 2022 Jun 20;13:805960
pubmed: 35795202
Front Immunol. 2019 May 10;10:954
pubmed: 31134065
Expert Opin Ther Targets. 2018 Aug;22(8):675-686
pubmed: 29999426
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Cancer Cell. 2021 Dec 13;39(12):1594-1609.e12
pubmed: 34767762
Mol Cancer. 2014 May 29;13:129
pubmed: 24886523
Clin Cancer Res. 2021 Jan 1;27(1):342-354
pubmed: 33046519
Front Oncol. 2018 Dec 12;8:608
pubmed: 30631751
Nat Rev Cancer. 2018 Mar;18(3):139-147
pubmed: 29326431
Nature. 2018 Dec;564(7735):268-272
pubmed: 30479382
Cancer Prev Res (Phila). 2018 Mar;11(3):125-128
pubmed: 29476043
Cell Death Differ. 2022 May;29(5):911-920
pubmed: 35332311
Nat Commun. 2013;4:2612
pubmed: 24113773
Nat Rev Cancer. 2011 Jul 07;11(8):558-72
pubmed: 21734724